+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Chronic kidney disease and kidney failure most often develop in adults, especially those with diabetes or high blood pressure. Over time, the kidneys lose their ability to filter waste and balance minerals, which can lead to serious complications. Re...

Search Bar & Filters

Found 85 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of Azvudine, a nucleoside reverse transcriptase inhibitor and broad-spectrum RNA virus inhibitor, on people with mild to moderate renal insufficiency and healthy individuals. This Phase 1 trial aims to understand how different levels of kidney function affect the drugs behavior in the body, its safety, and how well it is tolerated. The study is sponsored by Henan Genuine Biotech Co., Ltd. and involves adult participants aged 18 to 70 years old. Participants receive a single oral dose of 3 mg Azvudine tablets three tablets taken on an empty stomach on the first day of the study. The trial includes three groups those with mildly decreased kidney function, those with moderately decreased kidney function, and healthy volunteers matched by age, weight, and gender. The study uses an open-label, non-randomized, parallel design to monitor how the drug is processed in these groups. During the trial, blood and urine samples are collected up to 48 and 72 hours after dosing, respectively, to measure drug levels and other pharmacokinetic parameters. Safety exams and monitoring for any adverse effects occur from enrollment until day 4. Researchers evaluate outcomes such as maximum drug concentration, area under the concentration-time curve, and elimination half-life to understand the drugs behavior in participants with varying kidney function. The total study period includes screening, drug administration, and follow-up assessments.

Age: 18Years - 70YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
U

Actively Recruiting

Researchers are evaluating whether using a digital smartphone application can help adults with chronic kidney disease CKD better follow the 2024 Kidney Disease Improving Global Outcomes KDIGO guidelines. The study focuses especially on young adults transitioning from pediatric to adult nephrology care, who face higher risks and challenges during this vulnerable period. The research aims to improve treatment adherence and health outcomes by addressing gaps in current care and guideline implementation. Participants will use a modified version of the St. Jamess Hospital Renal App, which has been adapted to align with the KDIGO 2024 guidelines. The app provides tailored recommendations, reminders, educational materials, and collects patient-reported outcomes. The study uses a randomized stepped wedge design where patients receive first exposure and later continued use of the app. The intervention supports healthcare providers by highlighting opportunities for evidence-based therapies and helps patients manage their care digitally. During the study, participants will be monitored for changes in adherence to KDIGO guidelines over 18 months. Assessments will include patient engagement, clinical data integration via electronic health records, and patient-reported measures. The app also supports appointment management and medication reminders, aiming to enhance self-management and slow CKD progression. The research includes diverse patient subgroups and considers cultural and linguistic needs to promote equitable care.

Age: 16Years - 30YearsAll GendersPhase Not Applicable
2 locations
R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of AP1189 in patients with idiopathic membranous nephropathy iMN who have severe proteinuria. This exploratory, randomized, double-blind, placebo-controlled study focuses on patients already receiving ACE inhibitor or angiotensin II receptor blocker treatment, aiming to understand how AP1189 affects these patients over a 12-week period. Participants will be randomly assigned in a 21 ratio to receive either 100 mg of AP1189 or a matching placebo daily for 12 weeks, alongside their ongoing treatments. The study is conducted at multiple centers and maintains a triple-blind design to ensure unbiased results. The AP1189 and placebo are administered as tablets taken once each day during the treatment period. During the study, participants will undergo regular monitoring including assessments of adverse events, blood tests for liver enzymes and bilirubin, and measurements of protein levels in urine over 24 hours. Researchers will also track albumin levels in urine. These evaluations occur up to week 12, covering safety and treatment effects. The studys total duration includes screening, 12 weeks of treatment, and follow-up to capture all relevant data on patient health and response to the investigational drug.

Age: 18Years - 85YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the pharmacokinetics and safety of golcadomide BMS-986369 in different participant groups. These groups include healthy adults with normal kidney function, adults with severe renal impairment, and those with end-stage renal disease. The study aims to understand how the drug behaves in the body and its safety profile across these kidney function levels. Participants receive a single specified dose of golcadomide during the study. The study uses a parallel design with three groups healthy participants with normal renal function, participants with severe renal impairment, and participants with end-stage renal disease. Each group receives the drug and is monitored accordingly. Participants will undergo monitoring for up to 44 days to measure drug concentration levels in the blood, including maximum concentration, time to reach maximum concentration, and area under the plasma concentration-time curve. Safety evaluations, including physical exams, vital signs, ECGs, and laboratory tests, occur up to 44 or 60 days. Dialysate clearance of golcadomide is measured on Day 1. The total participation duration spans up to approximately two months.

Age: 18Years - 84YearsAll GendersPhase 1
3 locations
L

Actively Recruiting

Researchers are evaluating a new way to treat children aged 1 to 18 years with chronic kidney disease CKD and proteinuria, a condition where kidneys leak protein into the urine. The study focuses on adding finerenone to existing treatments of angiotensin-converting enzyme inhibitors ACEI or angiotensin receptor blockers ARB, which are commonly used to control blood pressure and protect kidney function. The goal is to understand the long-term safety of finerenone combined with these standard treatments, as well as its effect on kidney health and protein levels in urine. Participants will receive finerenone adjusted for age and body weight alongside their current ACEI or ARB therapy. The treatment period lasts up to 18 months, followed by one month of follow-up. During this time, patients will attend at least 12 visits if newly starting finerenone or at least 8 visits if continuing from a previous study, where various health measurements and tests will be conducted. Throughout the study, researchers will monitor participants blood pressure, heart rate, temperature, height, weight, and kidney function through blood and urine tests. They will also perform physical exams, heart checks using electrocardiograms and echocardiography, and collect information on medication use and any side effects. Safety is a primary focus, with careful tracking of any medical problems that arise during treatment, plus a health check about 30 days after the last dose. The entire participation lasts approximately 19 months.

Age: 1Year - 18YearsAll GendersPhase 3
151 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the safety and pharmacokinetics of Hydronidone capsules, a pyridinone-based drug, in patients with renal insufficiency and healthy individuals. Hydronidone has shown promise in treating liver fibrosis in chronic hepatitis B through earlier clinical trials. This study aims to understand how the drug behaves in the body of patients with varying degrees of kidney dysfunction to guide safe medication use. Participants will receive a single oral dose of 90 mg Hydronidone capsules on an empty stomach on the morning of Day 1. The study includes four groups healthy volunteers, and patients with mild, moderate, or severe renal insufficiency. All participants take the medication once, and their responses are monitored. During the trial, participants will undergo blood and urine tests to measure drug and metabolite concentrations over 48 hours. Safety assessments include ultrasounds of various organs and electrocardiograms performed 72 hours after dosing. Researchers will track any adverse events and evaluate the bodys handling of the drug to ensure safety and understand drug behavior in people with kidney issues. Participation lasts a few days with close monitoring.

Age: 18Years - 70YearsAll GendersPhase 1
1 location
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy caused by various conditions like diabetes, hypertension, autoimmune diseases, and chronic kidney disease CKD stages 1 to 5. The trial aims to determine if 12 weeks of ACE Reno treatment can reduce albuminuria or proteinuria and stabilize kidney function in these patients. Nephropathy is a significant global health issue affecting millions and leading to high socioeconomic costs worldwide. Participants will receive ACE Reno as a sublingual solution at a dose of 1 mL four times daily for 12 weeks. The solution contains peptide components designed to target pathways involved in kidney damage, including antifibrotic and vasodilatory mechanisms. This is an open-label, single-arm study with assessments at screening, baseline, weeks 4, 8, and 12, followed by a safety follow-up call at week 16. During the study, participants will undergo clinical evaluations including blood pressure, vital signs, weight, and laboratory tests such as creatinine, estimated glomerular filtration rate eGFR, electrolytes, liver panel, complete blood count, and urine albumin-to-creatinine ratio ACR. Patient-reported outcomes on fatigue and quality of life will also be collected. The primary outcome is the change in urinary ACR after 12 weeks. Safety and tolerability will be monitored throughout treatment and during the 4-week post-treatment follow-up period.

Age: 18Years - 80YearsAll GendersPhase 4
1 location
S

Actively Recruiting

This research aims to evaluate the use of activated charcoal in managing hyperphosphatemia, a condition common in patients with end-stage renal disease ESRD who are on dialysis. Hyperphosphatemia can contribute to worsening vascular calcification, and current management mainly involves limiting dietary phosphorus and using phosphate binders. Activated charcoal, which is generally well tolerated, is being studied as a possible alternative to conventional phosphate binders in dialysis patients. Participants are randomly assigned to one of two groups one group receives standard care with calcium-based or non-calcium based phosphate binders such as sevelamer, while the other group receives these standard binders plus oral activated charcoal capsules taken with meals. The study is double-blinded and conducted over 8 weeks to assess the effect of activated charcoal on mineral and bone disorder related to chronic kidney disease. During the study, participants will have their serum phosphorus levels measured to evaluate treatment effects. Researchers will also track the percentage of patients who experience a significant decrease in itching intensity using a numerical rating scale. The study includes safety monitoring and aims to gather data on both efficacy and side effects. Overall participation duration includes screening, treatment, and follow-up during the 8-week trial period.

Age: 18Years +All GendersPhase 2
1 location

1-10 of 85

1